Immune checkpoint inhibitors transformed melanoma treatment. They also leave a large share of patients behind, and figuring out what to do for those patients is the central unsolved problem in the field.
UCLA researchers have received a five-year, $3.9 million grant from the National Cancer Institute to work on it. The award goes to Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, according to UCLA Health. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy.
This is funding for research, not a result. Nothing has been shown to help any patient, and the work described is preclinical.
The Grant Is About Fixing Non-Response, Not Explaining It
A distinction worth drawing precisely, because it changes what to expect from this work.
The project is not primarily a study of why some patients respond, and others do not. It is drug development aimed at overcoming barriers already identified. Using a drug screening platform developed in the Puig-Saus laboratory to test thousands of compounds, the team identified two candidates, and the two work by different routes.
One appears to strengthen the interaction between T cells and cancer cells, helping the immune system mount a more effective attack. The other makes tumor cells more susceptible to destruction by T cells without directly altering the immune cells themselves. That second approach is notable because it sidesteps the problem of a patient’s T cells being exhausted or scarce.
The funding will support testing whether those compounds boost the effectiveness of existing immunotherapies in preclinical melanoma models, investigating how the drugs work, and evaluating their potential to be used safely. Puig-Saus has said that because the compounds are designed to work alongside existing immunotherapies, the approach could potentially apply across many cancer types.
Why So Many Patients Do Not Respond
The underlying problem is worth explaining, because it is what any approach has to solve.
Checkpoint inhibitors work by releasing the brakes on T cells so they can attack tumors. That only helps if T cells can find the tumor in the first place. Two failure modes dominate.
The first is recognition. T cells often struggle to identify cancer cells, particularly when tumors reduce the display of the surface molecules that mark a cell as abnormal. A tumor the immune system cannot see is not helped by removing a brake.
The second is evasion. Tumors evolve under immune pressure. They can lose the specific proteins T cells were targeting, recruit suppressive cells, or create a local environment that exhausts T cells. Tumors described as cold have few infiltrating T cells to begin with.
The scale of the gap is substantial. UCLA has previously reported that 40 percent of patients with melanoma do not respond to checkpoint blockade, with response especially poor in rarer forms including acral melanoma on the palms and soles, uveal melanoma in the eye, and mucosal melanoma.
The Screening Platform Is the Method Worth Noting
How the two candidate compounds were found says something about where cancer drug discovery has moved.
Rather than starting from a hypothesis about a single molecule, the laboratory built a screening platform capable of testing thousands of compounds for effects on the interaction between T cells and cancer cells. That approach asks which compounds change the behavior of the system, then works backward to understand why.
The advantage is that it can surface candidates nobody would have predicted from existing biology. The trade-off is that a compound identified this way arrives without a fully worked-out mechanism, which is precisely why part of the grant is devoted to investigating how the drugs work rather than only whether they work.
That mechanistic question is not academic. Understanding how a compound acts is what allows researchers to predict side effects, identify which patients might benefit, and design sensible combinations with existing immunotherapies.
The Timeline for Anything Reaching Patients
Preclinical grants are frequently reported in ways that imply proximity to treatment, and the arithmetic does not support that.
Five years of preclinical work would be followed, if results justify it, by formal toxicology studies, manufacturing under regulated conditions, and an investigational new drug application before a first human trial. That first trial would test safety and dosing rather than benefit. Efficacy testing would follow.
Most compounds entering this pipeline do not reach patients. That is not pessimism about this particular project; it is the base rate, and it is why the honest framing is that federal funding has been committed to a promising question.
What patients with melanoma can act on is different. Checkpoint inhibitors, targeted therapies for BRAF-mutant disease, and tumor-infiltrating lymphocyte therapy are all available now depending on tumor characteristics and prior treatment. Molecular testing of the tumor determines which apply.
For patients whose disease has progressed on checkpoint inhibitors, clinical trials are frequently the most substantive option, and enrollment is concentrated at academic and NCI-designated cancer centers. The same laboratory is separately advancing an experimental CAR T cell therapy for melanoma toward a trial, which is the kind of option worth asking an oncologist about directly.
Melanoma prevention and early detection remain the most effective interventions available. Anyone noticing a mole that changes in size, shape, or color, has an irregular border or uneven color, or looks different from other moles should have it examined. Early-stage melanoma is frequently curable with surgery alone.
This article is general information and is not medical advice.
Frequently Asked Questions
What was funded? A five-year, $3.9 million National Cancer Institute grant to Cristina Puig-Saus at UCLA.
What will the money support? Preclinical testing of two compounds identified through a drug screening platform, aimed at boosting existing immunotherapies in melanoma models.
How do the two compounds differ? One strengthens the interaction between T cells and cancer cells. The other makes tumor cells more vulnerable to T cells without altering the immune cells.
Why do checkpoint inhibitors fail in some patients? T cells often cannot recognize cancer cells, and tumors evolve to evade immune attack. UCLA has reported that 40 percent of melanoma patients do not respond.
Has anything been shown to work? No. This is funding for research. No patient benefit has been demonstrated.
When could this reach patients? Not for many years, if at all. Preclinical work precedes toxicology, manufacturing, and first-in-human safety trials.
What can melanoma patients do now? Ask about molecular testing, currently approved options, and open clinical trials, particularly at NCI-designated centers.
